Novel bispecific nanobody mitigates experimental intestinal inflammation in mice by targeting TNF‐α and IL‐23p19 bioactivities

Novel bispecific nanobody mitigates experimental intestinal inflammation in mice by targeting TNF‐α and IL‐23p19 bioactivities

Abstract Background Inflammatory bowel diseases (IBDs) pose significant challenges in terms of treatment non‐response, necessitating the development of novel therapeutic approaches. Although biological medicines that target TNF‐α (tumour necrosis factor‐α) have shown clinical success in some IBD pat...

Full description

Bibliographic Details
Main Authors: Jiewen Wang, Guangbo Kang, Huiying Lu, Ario deMarco, Haibin Yuan, Zelin Feng, Mengxue Gao, Xiaoli Wang, Huahong Wang, Xiaolan Zhang, Yuli Wang, Miao Zhang, Ping Wang, Yuanhang Feng, Zhanju Liu, Xiaocang Cao, He Huang
Format: Article
Language:English
Published: Wiley 2024-03-01
Series:Clinical and Translational Medicine
Subjects:
anti‐TNF‐α mAb
bispecific nanobodies
inflammatory bowel disease
TNFR2+IL23R+ T cells
VHH‐Fc
Online Access:https://doi.org/10.1002/ctm2.1636

Internet

https://doi.org/10.1002/ctm2.1636

Similar Items